News Release

Trading on the Toronto Stock Exchange Commences

Date: March 9, 2004

TSX Venture Exchange Trading Symbol: WXI
http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc. (the "Company" or "Wex") is pleased to announce that the Company's common shares will commence trading March 11, 2004 on the Toronto Stock Exchange. Wex will retain the trading symbol "WXI". As of market close March 10, 2004, the Company's common shares will no longer trade on the TSX Venture Exchange.

This move to a senior listing is significant as it will provide increased exposure and a much broader shareholder base.

Through years of research and development the Company's lead product Tectin™ is now cleared to commence a Phase IIb/III Pivotal trial in Canada and the Company will now implement its global development plan.

International Wex Technologies Inc., a publicly listed neuro-bioscience company (WXI), is focused on the development and commercialization of innovative drug products, primarily for pain management. The Company's lead compound, Tetrodotoxin, is a sodium channel blocker and is the platform for the Company's development of a portfolio of proprietary products in the field of analgesia, drug addiction withdrawal treatment, and local anaesthesia.

For additional information on our products visit us at http://www.wextech.ca or call Gordon Stanley, Corporate Communications at 604-683-8880, or at 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.